Cargando…
Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The International AIDS Society
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113052/ http://dx.doi.org/10.1186/1758-2652-13-S4-P49 |
| _version_ | 1782205877084749824 |
|---|---|
| author | Casado, JL Domingo, P Rubio, R Antela, A Lopez-Ruz, MA Castro, A Portilla, J Ribera, E Podzamczer, D Oteo, JA Galindo, J Otero, S Lozano, F Estrada, V Moltó, J Moreno, S |
| author_facet | Casado, JL Domingo, P Rubio, R Antela, A Lopez-Ruz, MA Castro, A Portilla, J Ribera, E Podzamczer, D Oteo, JA Galindo, J Otero, S Lozano, F Estrada, V Moltó, J Moreno, S |
| author_sort | Casado, JL |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3113052 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2010 |
| publisher | The International AIDS Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-31130522011-06-13 Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL Casado, JL Domingo, P Rubio, R Antela, A Lopez-Ruz, MA Castro, A Portilla, J Ribera, E Podzamczer, D Oteo, JA Galindo, J Otero, S Lozano, F Estrada, V Moltó, J Moreno, S J Int AIDS Soc Poster Presentation The International AIDS Society 2010-11-08 /pmc/articles/PMC3113052/ http://dx.doi.org/10.1186/1758-2652-13-S4-P49 Text en Copyright ©2010 Moreno et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Casado, JL Domingo, P Rubio, R Antela, A Lopez-Ruz, MA Castro, A Portilla, J Ribera, E Podzamczer, D Oteo, JA Galindo, J Otero, S Lozano, F Estrada, V Moltó, J Moreno, S Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL |
| title | Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL |
| title_full | Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL |
| title_fullStr | Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL |
| title_full_unstemmed | Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL |
| title_short | Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL |
| title_sort | switching from tipranavir (tpv) 500/ritonavir (rtv) 200 mg to tpv 500/rtv 100 mg in treatment-experienced patients (pts) with hiv rna <50 copies/ml |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113052/ http://dx.doi.org/10.1186/1758-2652-13-S4-P49 |
| work_keys_str_mv | AT casadojl switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT domingop switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT rubior switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT antelaa switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT lopezruzma switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT castroa switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT portillaj switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT riberae switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT podzamczerd switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT oteoja switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT galindoj switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT oteros switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT lozanof switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT estradav switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT moltoj switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml AT morenos switchingfromtipranavirtpv500ritonavirrtv200mgtotpv500rtv100mgintreatmentexperiencedpatientsptswithhivrna50copiesml |